Literature DB >> 16905590

Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.

R Peek, R Scott-Jupp, H Strike, J Clinch, A V Ramanan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16905590      PMCID： PMC1798298          DOI： 10.1136/ard.2005.049916

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  Psoriasiform eruption induced by infliximab.

Authors:  María M Verea; Jesús Del Pozo; M Teresa Yebra-Pimentel; Angeles Porta; Eduardo Fonseca
Journal:  Ann Pharmacother       Date:  2004-01       Impact factor: 3.154

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

3.  Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.

Authors:  O Dereure; B Guillot; C Jorgensen; J-D Cohen; B Combes; J-J Guilhou
Journal:  Br J Dermatol       Date:  2004-08       Impact factor: 9.302

4.  New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.

Authors:  S Kary; M Worm; H Audring; D Huscher; M Renelt; H Sörensen; E Ständer; U Maass; H Lee; W Sterry; G-R Burmester
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

5.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Authors:  P P Sfikakis; A Iliopoulos; A Elezoglou; C Kittas; A Stratigos
Journal:  Arthritis Rheum       Date:  2005-08

6.  Pustular psoriasis induced by infliximab.

Authors:  Marzieh Thurber; Adrienne Feasel; John Stroehlein; Sharon R Hymes
Journal:  J Drugs Dermatol       Date:  2004 Jul-Aug       Impact factor: 2.114

7.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156
  7 in total
  7 in total

1.  Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease.

Authors:  Laurie S Conklin; Bernard Cohen; Lindsay Wilson; Carmen Cuffari; Maria Oliva-Hemker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03       Impact factor: 46.802

Review 2.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

3.  Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.

Authors:  Lisa H Buckley; Rui Xiao; Marissa J Perman; Andrew B Grossman; Pamela F Weiss
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-01-03       Impact factor: 4.794

Review 4.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

5.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06

6.  The changing face of spondyloarthropathies under TNF α blockade.

Authors:  Ori Elkayam; Irena Litinsky; David Levartovsky; Dan Caspi
Journal:  Open Rheumatol J       Date:  2008-11-14

7.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  M J Harrison; W G Dixon; K D Watson; Y King; R Groves; K L Hyrich; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-04-02       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.